Edgewell Personal Care heads into its August earnings window with a notable split: the Street is turning more constructive just as short sellers maintain a meaningful position — and the stock has already rallied 34% over the past month.
Two analyst upgrades in two days have set the tone this week. Wells Fargo's Chris Carey lifted his price target to $30 from $24 on July 8, keeping his Overweight rating, while Canaccord Genuity raised its target to $34 from $32 on July 7, reaffirming Buy. Both moves confirm that the Street's bulls are chasing the stock higher — the consensus mean target has reached $24.83, though with EPC now trading at $26.61, the stock has already blown past the average. The implied upside from consensus is essentially gone, though the high-conviction bulls at Canaccord and Wells Fargo are still reaching for $30-plus. That divergence between the mean and the bulls deserves attention: it suggests the analyst community is dragging its collective target upward rather than leading the move.
Short interest remains a genuine feature of this stock, not background noise. Bears control roughly 12.4% of the free float — a position that has barely budged over the past month, down just 1% in 30 days. After a brief uptick this week (shares short edged up about 1.5% on July 7), the pace of covering has stalled. The ORTEX short score sits at 62, consistent across the past ten sessions, marking a moderately elevated bearish signal. That said, the borrow market does not support a squeeze thesis. Availability runs at 449% — nearly five available shares for every one currently borrowed — and cost to borrow is just 0.60%, barely above its recent range. Bears face no meaningful squeeze pressure at these borrow conditions; the position is comfortable to hold.
Options positioning is not adding much signal this week. The put/call ratio at 0.55 is marginally below its 20-day average of 0.57, with a z-score effectively flat at -0.10. That places sentiment in neutral territory — neither hedging into the August 5 earnings date nor expressing directional conviction through calls. The contrast with early June is worth noting: back on June 10-12, the PCR ran near 0.96-0.98, reflecting clear defensiveness around then. That fear has since unwound entirely.
The ownership story adds an interesting wrinkle. Rubric Capital Management disclosed a 4 million share position — 8.7% of shares outstanding — with a reported addition of nearly 3 million shares in the March quarter, making it the fourth-largest holder. That is a concentrated, high-conviction bet from an active manager, entered when the stock was materially lower. American Century also added over 800,000 shares through May. Against that backdrop of institutional accumulation, the persistent short position at 12% looks more like a structural disagreement than a crowded trade — value buyers on one side, bears citing North American volume declines and tariff headwinds on the other.
The earnings record makes the August 5 date the next live wire. The two most recent prints both produced immediate single-day drops — down 9.1% in May after Q2 results, and down 5.2% for the prior release. Both were followed by extended five-day slides of 26% and 20% respectively. The stock has already recouped those losses and more with its 34% monthly rally, but that history of post-earnings weakness, combined with a 12% short base that has not capitulated, sets up August 5 as a decisive test of whether this recovery has fundamental legs or has simply run ahead of the numbers.
What to watch: whether the analyst community closes the gap between the $24.83 consensus target and the two bullish outliers at $30-34, and whether any short covering materialises before the August print or stays patient into the release.
See the live data behind this article on ORTEX.
Open EPC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
